Dutch Biopharmaceutical Company AM-Pharma Strengthens Intellectual Property Position for Lactoferrin Derived Antimicrobial Peptide hLF1-11

Bunnik, The Netherlands (ots/PRNewswire) - AM-Pharma B.V., abiopharmaceutical company engaged in the pre-clinical and earlyclinical development of novel compounds to treat infectious andinflammatory diseases, announces the issuance of the patent for oneof its lead products, the antimicrobial peptide hLF1-11, by the USand EU patent offices (US patent 7,060,677 and European patent1228097). The patents claim the use of the hLF1-11 peptide and itsderivatives, to produce drugs with high efficacy against a broadspectrum of bacterial, fungal and viral infections.

Among others, AM-Pharma research has been aimed at testing avariety of human lactoferrin derivatives for their antimicrobialactivity. The first lead compound that emerged from this research,hLF1-11, consists of the first eleven amino acids of the naturalhuman lactoferrin. Safety and efficacy of the peptide wassuccessfully demonstrated in pre-clinical animal models. No toxicityand no adverse reactions were observed in both single dose andmultiple ascending doses studies. Recent results from Phase Iclinical trials in humans show that hLF1-11 is safe and induced nosigns of toxicity, immune responses or other adverse events thatcould be attributed to the peptide.

Based on these findings hLF1-11 is currently evaluated in a PhaseII trial as an effective and safe antibacterial and antifungalsubstance for the prevention of severe fungal and bacterialinfections, especially in patient undergoing bone marrow stem celltransplantations (UMC St Radboud, Nijmegen, The Netherlands). In thispopulation, incidence rates of severe infections and relatedmortality are high. This provides an important indication toestablish early clinical proof-of-principle. AM-Pharma has generatedsubstantial pre-clinical data to support this indication. Dr. BrunoGiannetti, President & Chief Executive of AM-Pharma: "The granting ofthese patents forms the basis for the development of a novel classof antibiotics for the treatment of systemic infections." AM-Pharmais currently validating additional indications for this leadcompound.

AM-Pharma is a clinical stage biopharmaceutical company based inBunnik, the Netherlands. The company's business is focused on thepreclinical and early clinical development of novel compounds in thefield of severe infectious diseases and their consequences, as wellas inflammatory diseases. AM-Pharma currently employs 22 staff and isfinanced by ABN-AMRO Capital Life Sciences and Inventages VentureCapital.

This release contains forward-looking statements that are notbased on historical facts. These forward-looking statements involverisks, uncertainties and other factors that may cause the actualresults, events or developments to be materially different from thoseexpressed or implied by such forward-looking statements. Readers arecautioned not to place undue reliance

Visit the company's website at www.AM-Pharma.com

ots Originaltext: AM-Pharma B.V.Im Internet recherchierbar: http://www.presseportal.de

Contact:For further information about AM-Pharma, please contact Markwin Velders (CSO) or Bruno Giannetti (CEO) on +31-30-228-9-222, email m.velders@am-pharma.com and b.giannetti@am-pharma.com

AM-Pharma B.V.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Dutch Biopharmaceutical Company AM-Pharma Strengthens Intellectual Property Position for Lactoferrin Derived Antimicrobial Peptide hLF1-11